Detection of somatic BRCA1/2 mutations in ovarian cancer – next‐generation sequencing analysis of 100 cases

The overall prevalence of germline BRCA1/2 mutations is estimated between 11% and 15% of all ovarian cancers. Individuals with germline BRCA1/2 alterations treated with the PARP1 inhibitors (iPARP1) tend to respond better than patients with wild‐type BRCA1/2. Additionally, also somatic BRCA1/2 alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Koczkowska, Magdalena, Zuk, Monika, Gorczynski, Adam, Ratajska, Magdalena, Lewandowska, Marzena, Biernat, Wojciech, Limon, Janusz, Wasag, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867663/
https://www.ncbi.nlm.nih.gov/pubmed/27167707
http://dx.doi.org/10.1002/cam4.748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867663/
https://www.ncbi.nlm.nih.gov/pubmed/27167707
http://dx.doi.org/10.1002/cam4.748

Ejemplares similares